246 related articles for article (PubMed ID: 27183138)
1. Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol.
Cernigliaro JG; Haley WE; Adolphson DP; Jepperson MA; Crook JE; Thomas CS; Parker AS
Clin Imaging; 2016; 40(5):902-6. PubMed ID: 27183138
[TBL] [Abstract][Full Text] [Related]
2. Comparison of iodixanol and iohexol in patients undergoing intravenous pyelography: a prospective controlled study.
Chuang FR; Chen TC; Wang IK; Chuang CH; Chang HW; Ting-Yu Chiou T; Cheng YF; Lee WC; Chen WC; Yang KD; Lee CH
Ren Fail; 2009; 31(3):181-8. PubMed ID: 19288321
[TBL] [Abstract][Full Text] [Related]
3. Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.
Cheruvu B; Henning K; Mulligan J; Klippenstein D; Lawrence D; Gurtoo L; Gottlieb RH
J Comput Assist Tomogr; 2007; 31(4):493-8. PubMed ID: 17882021
[TBL] [Abstract][Full Text] [Related]
4. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials.
From AM; Al Badarin FJ; McDonald FS; Bartholmai BJ; Cha SS; Rihal CS
Circ Cardiovasc Interv; 2010 Aug; 3(4):351-8. PubMed ID: 20647563
[TBL] [Abstract][Full Text] [Related]
5. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients.
Solomon R
Kidney Int; 2005 Nov; 68(5):2256-63. PubMed ID: 16221227
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
[TBL] [Abstract][Full Text] [Related]
8. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.
Terrenato I; Sperati F; Musicco F; Pozzi AF; di Turi A; Caterino M; de Lutio di Castelguidone E; Setola SV; Bellomi M; Neumaier CE; Conti L; Cigliana G; Merola R; Antenucci A; Orlandi G; Giordano A; Barba M; Canitano S
J Cell Physiol; 2018 Mar; 233(3):2572-2580. PubMed ID: 28777459
[TBL] [Abstract][Full Text] [Related]
9. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
[TBL] [Abstract][Full Text] [Related]
10. Risk of contrast-induced nephropathy for patients receiving intravenous vs. intra-arterial iodixanol administration.
Tong GE; Kumar S; Chong KC; Shah N; Wong MJ; Zimmet JM; Wang ZJ; Yee J; Fu Y; Yeh BM
Abdom Radiol (NY); 2016 Jan; 41(1):91-9. PubMed ID: 26830615
[TBL] [Abstract][Full Text] [Related]
11. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
[TBL] [Abstract][Full Text] [Related]
12. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy.
Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Lundkvist J
Am Heart J; 2005 Feb; 149(2):298-303. PubMed ID: 15846268
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
Song T; Song M; Ge Z; Li Y; Shi P; Sun M
J Interv Cardiol; 2017 Jun; 30(3):281-285. PubMed ID: 28421628
[TBL] [Abstract][Full Text] [Related]
16. Contrast-induced nephropathy in urgent coronary interventions.
Valente S; Lazzeri C; Giglioli C; Margheri M; Comeglio M; Nicolaci L; Chechi T; Gensini GF
J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):737-41. PubMed ID: 17001234
[TBL] [Abstract][Full Text] [Related]
17. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality.
McDonald RJ; McDonald JS; Carter RE; Hartman RP; Katzberg RW; Kallmes DF; Williamson EE
Radiology; 2014 Dec; 273(3):714-25. PubMed ID: 25203000
[TBL] [Abstract][Full Text] [Related]
18. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
[TBL] [Abstract][Full Text] [Related]
19. Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho AL; O'Malley ME; Tomlinson GA
J Comput Assist Tomogr; 2007; 31(2):165-8. PubMed ID: 17414747
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy.
Chicaíza-Becerra LA; García-Molina M; Gamboa Ó
Biomedica; 2012 Jun; 32(2):182-8. PubMed ID: 23242291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
